Journal articleJ Gastrointest Oncol2016
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
- Journal
- J Gastrointest Oncol
- Published
- 1 June 2016
- Citations
- 48
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 3
- BackgroundEfficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer NCT03502343↗
- BackgroundA Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046. NCT02021500↗
- BackgroundPhase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma o… NCT00844649↗